Humacyte (NASDAQ:HUMA) Price Target Raised to $12.00 at HC Wainwright

Humacyte (NASDAQ:HUMA) had its target price lifted by HC Wainwright from $6.00 to $12.00 in a research note published on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Humacyte’s FY2028 earnings at $0.71 EPS.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. TD Cowen reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Benchmark reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. Finally, Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humacyte presently has a consensus rating of “Buy” and an average target price of $11.00.

Humacyte Price Performance

Shares of Humacyte stock opened at $5.22 on Tuesday. The firm has a market cap of $623.01 million, a PE ratio of -4.14 and a beta of 1.47. The stock has a 50 day moving average of $5.51 and a 200 day moving average of $6.12. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte has a 12 month low of $2.08 and a 12 month high of $9.97.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, research analysts expect that Humacyte will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the transaction, the director now directly owns 40,276 shares in the company, valued at $217,490.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 157,704 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the transaction, the chief executive officer now owns 3,519,558 shares in the company, valued at approximately $19,076,004.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock valued at $6,869,996 in the last 90 days. Company insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of HUMA. Renaissance Technologies LLC lifted its holdings in Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the period. Virtu Financial LLC bought a new stake in Humacyte during the first quarter valued at about $197,000. Private Advisor Group LLC grew its stake in Humacyte by 232.7% in the first quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after purchasing an additional 222,144 shares during the last quarter. Vanguard Group Inc. raised its holdings in Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Humacyte by 504.3% during the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.